Research across Multiple Sclerosis
Related studies from across the Multiple Sclerosis family.
Rituximab is noninferior to ocrelizumab in suppressing T2-weighted MRI lesions from month 6 to 24
Trial shows rituximab works as well as ocrelizumab for MS
This Phase 3 randomized controlled trial of 218 adults with newly diagnosed relapsing multiple sclerosis found rituximab noninferior to ocre…
A new study finds that two different treatments for multiple sclerosis show similar success in stopping brain lesions and managing disease a…
Extended-interval natalizumab dosing shows no significant difference in disability progression for relapsing-remitting multiple sclerosis
Extended dosing of natalizumab shows similar outcomes for multiple sclerosis
This meta-analysis of patients with relapsing-remitting multiple sclerosis found that extended-interval dosing (EID) of natalizumab did not …
New data suggests that spacing out natalizumab doses may work as well as standard schedules for patients with relapsing-remitting multiple s…
Verbal fluency is significantly impaired in multiple sclerosis and neuromyelitis optica spectrum disorders
Speech Fluency Linked to Cognitive Function in MS and NMOSD
This meta-analysis of 69 studies evaluates verbal fluency in patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorde…
People with multiple sclerosis and NMOSD often show lower verbal fluency scores compared to healthy individuals, highlighting a link to cogn…
Nabiximols reduces pain and spasticity in multiple sclerosis patients
Nabiximols reduces pain and spasticity in MS patients
A meta-analysis of Sativex (nabiximols) shows significant reductions in pain and spasticity, with modest disability improvement in MS patien…
A new analysis finds that Sativex (nabiximols) significantly eases pain and spasticity in people with multiple sclerosis.
Optical coherence tomography shows significantly reduced retinal measurements in neuromyelitis optica spectrum disorder compared to multiple sclerosis
Retinal Scans Show Distinct Differences Between MS and NMOSD
This systematic review and meta-analysis analyzed OCT measurements in patients with multiple sclerosis (PwMS) and neuromyelitis optica spect…
New analysis shows that eye scans reveal significant differences in retinal thickness and volume between people with MS and those with NMOSD…
Cladribine tablets reduce annualized relapse rate by 58% compared to placebo in active RRMS
Cladribine tablets show promise for managing relapsing-remitting multiple sclerosis
This systematic review and network meta-analysis of 66 studies evaluated cladribine against various disease-modifying treatments for relapsi…
New data shows cladribine tablets significantly reduce relapse rates and slow disease progression in people with active relapsing-remitting …
Serum neurofilament light chain serves as a robust biomarker of recent neuroaxonal injury in Multiple Sclerosis
Blood tests may help track nerve damage in Multiple Sclerosis
This guideline evaluates serum neurofilament light chain (sNfL) as a blood-based biomarker for multiple sclerosis. The evidence indicates sN…
A new blood marker called sNfL can help doctors see recent nerve damage and predict future disability risk in people with Multiple Sclerosis…
Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders
Diabetes May Influence Risk and Progress of Neurological Disorders
This narrative review synthesizes evidence regarding the role of diabetes mellitus (DM) as a disease modifier across various neurological co…
New research suggests that diabetes can change how certain neurological conditions progress, potentially opening doors for new treatment opt…
NfL serves as a sensitive biomarker for RRMS progression while GFAP lacks independent prognostic value
Protein levels help predict multiple sclerosis relapses and disability
This meta-analysis of 4,016 individuals with multiple sclerosis evaluates NfL and GFAP as biomarkers for relapses and disability progression…
A specific protein called NfL can help doctors predict relapses and the worsening of physical disability in people with multiple sclerosis.
Aging impacts multiple sclerosis pathobiology by shifting inflammation toward chronic, compartmentalized neuroinflammation and neurodegeneration
New research explores how aging changes multiple sclerosis treatment
This narrative review examines the impact of aging on the immunological and neuroinflammatory microenvironment in older patients with multip…
As people age, multiple sclerosis can change from sudden flare-ups to a slow, steady progression of nerve damage.
Menopause does not appear to be a distinct clinical inflection point for multiple sclerosis progression
Menopause does not appear to be a turning point for MS
This narrative review examines the impact of menopause and biological aging on women with multiple sclerosis. The authors conclude that whil…
While menopause can make symptoms harder to manage, it is not a clear biological turning point for the progression of multiple sclerosis.
Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation
Dietary nutrients show mixed results for brain diseases in lab and early human data
This narrative review synthesizes evidence on nutrients and metabolites for Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic la…
Nutrients like vitamins and marine compounds show promise in labs, but human evidence for brain diseases remains inconsistent and unclear.